Literature DB >> 19590652

Renal haemodynamics and function following partial portal decompression.

Sharona Ross1, Donald Thometz, Francesco Serafini, Mark Bloomston, Connor Morton, Emmanuel Zervos, Alexander Rosemurgy.   

Abstract

BACKGROUND: This study was undertaken to prospectively evaluate the impact of partial portal decompression on renal haemodynamics and renal function in patients with cirrhosis and portal hypertension.
METHODS: Fifteen consecutive patients (median age 49 years) with cirrhosis underwent partial portal decompression through portacaval shunting or transjugular intrahepatic portosystemic shunting (TIPS). Cirrhosis was caused by alcohol in 47%, hepatitis C in 13%, both in 33% and autoimmune factors in 7% of patients. Child class was A in 13%, B in 20% and C in 67% of patients. The median score on the Model for End-stage Liver Disease (MELD) was 14.0 (mean 15.0 +/- 7.7). Serum creatinine (SrCr) and creatinine clearance (CrCl) were determined pre-shunt, 5 days after shunting and 1 year after shunting. Colour-flow Doppler ultrasound of the renal arteries was also undertaken with calculation of the resistive index (RI) and pulsatility index (PI). Changes in the portal vein-inferior vena cava pressure gradient with shunting were determined.
RESULTS: With shunting, the portal vein-inferior vena cava gradients dropped significantly, with significant increases in PI in the early period after shunting. Creatinine clearance improved in the early post-shunt period. However, SrCr levels did not significantly improve. At 1 year after shunting, both CrCl and SrCr levels tended towards pre-shunt levels and the increase in PI did not persist. DISCUSSION: Partial portal decompression improves mild to moderate renal dysfunction in patients with cirrhosis. Early improvements in renal function after shunting begin to disappear by 1 year after shunting.

Entities:  

Keywords:  Renal haemodynamics; portacaval shunting; renal function

Year:  2009        PMID: 19590652      PMCID: PMC2697893          DOI: 10.1111/j.1477-2574.2009.00040.x

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  25 in total

1.  Transjugular intrahepatic portosystemic shunt vs. small-diameter prosthetic H-graft portacaval shunt: extended follow-up of an expanded randomized prospective trial.

Authors:  A S Rosemurgy; F M Serafini; B R Zweibel; T J Black; B T Kudryk; H J Nord; S E Goode
Journal:  J Gastrointest Surg       Date:  2000 Nov-Dec       Impact factor: 3.452

2.  A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts.

Authors:  M Malinchoc; P S Kamath; F D Gordon; C J Peine; J Rank; P C ter Borg
Journal:  Hepatology       Date:  2000-04       Impact factor: 17.425

3.  Transjugular intrahepatic portal-systemic shunt in the treatment of refractory ascites: effect on clinical, renal, humoral, and hemodynamic parameters.

Authors:  J Quiroga; B Sangro; M Núñez; I Bilbao; J Longo; L García-Villarreal; J M Zozaya; M Betés; J I Herrero; J Prieto
Journal:  Hepatology       Date:  1995-04       Impact factor: 17.425

4.  MELD score is better than Child-Pugh score in predicting 3-month survival of patients undergoing transjugular intrahepatic portosystemic shunt.

Authors:  Francesco Salerno; Manuela Merli; Massimo Cazzaniga; Valentina Valeriano; Plinio Rossi; Andrea Lovaria; Daniele Meregaglia; Antonio Nicolini; Lorenzo Lubatti; Oliviero Riggio
Journal:  J Hepatol       Date:  2002-04       Impact factor: 25.083

5.  Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion.

Authors:  M Guevara; P Ginès; G Fernández-Esparrach; P Sort; J M Salmerón; W Jiménez; V Arroyo; J Rodés
Journal:  Hepatology       Date:  1998-01       Impact factor: 17.425

6.  Transjugular intrahepatic portosystemic shunts for refractory ascites: assessment of clinical and hormonal response and renal function.

Authors:  K A Somberg; J R Lake; S J Tomlanovich; J M LaBerge; V Feldstein; N M Bass
Journal:  Hepatology       Date:  1995-03       Impact factor: 17.425

7.  The renal and hemodynamic effects of the peritoneovenous shunt for intractable hepatic ascites.

Authors:  L M Blendis; P D Greig; B Langer; R S Baigrie; J Ruse; B R Taylor
Journal:  Gastroenterology       Date:  1979-08       Impact factor: 22.682

8.  Hepatorenal syndrome: resolution after transjugular intrahepatic portosystemic shunt.

Authors:  T M Sturgis
Journal:  J Clin Gastroenterol       Date:  1995-04       Impact factor: 3.062

9.  Renal resistive indexes: variability in Doppler US measurement in a healthy population.

Authors:  M T Keogan; M A Kliewer; B S Hertzberg; D M DeLong; R H Tupler; B A Carroll
Journal:  Radiology       Date:  1996-04       Impact factor: 11.105

10.  Comparison of MELD, Child-Pugh, and Emory model for the prediction of survival in patients undergoing transjugular intrahepatic portosystemic shunting.

Authors:  Michael Schepke; Felix Roth; Rolf Fimmers; Karl August Brensing; Thomas Sudhop; Hans H Schild; Tilman Sauerbruch
Journal:  Am J Gastroenterol       Date:  2003-05       Impact factor: 10.864

View more
  2 in total

1.  Renal blood flow before and after portosystemic shunt in children with portal hypertension.

Authors:  Makhmud M Aliev; Rustam Z Yuldashev; Gulnara S Adilova; Gulnora A Yusupaileva
Journal:  Pediatr Surg Int       Date:  2014-03       Impact factor: 1.827

2.  Nonalcoholic Fatty Liver Disease and Diabetes Mellitus Are Associated With Post-Transjugular Intrahepatic Portosystemic Shunt Renal Dysfunction: An Advancing Liver Therapeutic Approaches Group Study.

Authors:  Jin Ge; Jennifer C Lai; Justin Richard Boike; Margarita German; Nathaniel Jest; Giuseppe Morelli; Erin Spengler; Adnan Said; Alexander Lee; Alexander Hristov; Archita P Desai; Shilpa Junna; Bhupesh Pokhrel; Thomas Couri; Sonali Paul; Catherine Frenette; Nathaniel Christian-Miller; Marcela Laurito; Elizabeth C Verna; Usman Rahim; Aparna Goel; Arighno Das; Stewart Pine; Dyanna Gregory; Lisa B VanWagner; Kanti Pallav Kolli
Journal:  Liver Transpl       Date:  2021-01-02       Impact factor: 5.799

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.